{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:11:23Z","timestamp":1789722683805,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.cllc.2017.01.009","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T19:02:04Z","timestamp":1486062124000},"page":"316-323.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Non\u2013Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non\u2013Small-cell Lung Cancer Favor Adenocarcinoma"],"prefix":"10.1016","volume":"18","author":[{"given":"Iris","family":"Shiran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomit","family":"Jessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Kamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbal","family":"Daniel-Meshulam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossie","family":"Navon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Onn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1224-3646","authenticated-orcid":false,"given":"Jair","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2017.01.009_bib1","series-title":"World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart","year":"2004"},{"key":"10.1016\/j.cllc.2017.01.009_bib2","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2012.46.9270","article-title":"New pathologic classification of lung cancer: relevance for clinical practice and clinical trials","volume":"31","author":"Travis","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib3","first-page":"3340","article-title":"A\u00a0preliminary transcriptome map of non\u2013small-cell lung cancer","volume":"62","author":"Fujii","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2017.01.009_bib4","doi-asserted-by":"crossref","first-page":"13790","DOI":"10.1073\/pnas.191502998","article-title":"Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses","volume":"98","author":"Bhattacharjee","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cllc.2017.01.009_bib5","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1200\/JCO.2005.03.8224","article-title":"Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors","volume":"24","author":"Takeuchi","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib6","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2017.01.009_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non\u2013small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib8","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2017.01.009_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non\u2013small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non\u2013small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib11","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1158\/1078-0432.CCR-11-1404","article-title":"New strategies for treatment of ALK-rearranged non\u2013small-cell lung cancers","volume":"17","author":"Sasaki","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2017.01.009_bib12","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/1078-0432.CCR-10-1591","article-title":"Targeting anaplastic lymphoma kinase in lung cancer","volume":"17","author":"Shaw","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2017.01.009_bib13","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non\u2013small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2017.01.009_bib14","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non\u2013small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1634\/theoncologist.2008-0232","article-title":"The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies","volume":"14","author":"Scagliotti","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2017.01.009_bib16","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non\u2013small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2017.01.009_bib17","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non\u2013small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JTO.0b013e3181d57f6e","article-title":"Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift","volume":"5","author":"Travis","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/JTO.0b013e3181c6ed9b","article-title":"Refining the diagnosis and EGFR status of non\u2013small-cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5\/6, and P63, and EGFR mutation analysis","volume":"5","author":"Nicholson","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib20","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/JTO.0b013e3181d40fac","article-title":"Subtyping of undifferentiated non\u2013small-cell carcinomas in bronchial biopsy specimens","volume":"5","author":"Loo","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib22","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/modpathol.2011.92","article-title":"Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens","volume":"24","author":"Rekhtman","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cllc.2017.01.009_bib23","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1002\/cncr.25830","article-title":"Immunohistochemical subtyping of non\u2013small-cell lung cancer not otherwise specified in fine-needle aspiration cytology: a\u00a0retrospective study of 103 cases with surgical correlation","volume":"117","author":"Righi","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2017.01.009_bib24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1309\/AJCPFKOLGL6PMOF3","article-title":"Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens","volume":"136","author":"Ocque","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cllc.2017.01.009_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/PAS.0b013e3182036d05","article-title":"Subclassification of non\u2013small-cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5\/6","volume":"35","author":"Mukhopadhyay","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cllc.2017.01.009_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/1066896913511527","article-title":"Does immunohistochemistry affect response to therapy and survival of inoperable non\u2013small-cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases","volume":"22","author":"Pelosi","year":"2014","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.cllc.2017.01.009_bib27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/JTO.0b013e318211dd16","volume":"6","author":"Pelosi","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"issue":"Suppl\u00a01","key":"10.1016\/j.cllc.2017.01.009_bib28","first-page":"S45","article-title":"The efficacy of pemetrexed-based treatment for advanced non\u2013small-cell lung cancer (NSCLC), as correlated with the pathologic features of tumors","volume":"7","author":"Shiran","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib29","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1309\/AJCP77KMKJXNMPMS","article-title":"Tissue-sparing application of the newly proposed IASLC\/ATS\/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact","volume":"137","author":"Sterlacci","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cllc.2017.01.009_bib30","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/modpathol.2012.58","article-title":"A\u00a0grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma","volume":"25","author":"Kadota","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cllc.2017.01.009_bib31","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/PAS.0b013e3181e4ee32","article-title":"A\u00a0grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors","volume":"34","author":"Sica","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cllc.2017.01.009_bib32","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/modpathol.2010.232","article-title":"Impact of proposed IASLC\/ATS\/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases","volume":"24","author":"Yoshizawa","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cllc.2017.01.009_bib33","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jtcvs.2005.12.057","article-title":"Histologic grade is an independent prognostic factor for survival in non\u2013small-cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases","volume":"131","author":"Sun","year":"2006","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2017.01.009_bib34","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.1986.4.5.702","article-title":"Long-term survivors in metastatic non\u2013small-cell lung cancer: an Eastern Cooperative Oncology Group study","volume":"4","author":"Finkelstein","year":"1986","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMsa1211127","article-title":"50-Year trends in smoking-related mortality in the United States","volume":"368","author":"Thun","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2017.01.009_bib36","first-page":"5","article-title":"Ratio of neutrophil to lymphocyte counts\u2013rapid and simple parameter of systemic inflammation and stress in critically ill","volume":"102","author":"Zahorec","year":"2001","journal-title":"Bratisl Lek Listy"},{"key":"10.1016\/j.cllc.2017.01.009_bib37","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/bjc.2013.332","article-title":"Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer","volume":"109","author":"Stotz","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2017.01.009_bib38","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.eururo.2014.02.042","article-title":"Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy","volume":"66","author":"Viers","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.cllc.2017.01.009_bib39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jtcvs.2008.05.046","article-title":"Neutrophil\/lymphocyte ratio and its association with survival after complete resection in non\u2013small-cell lung cancer","volume":"137","author":"Sarraf","year":"2009","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2017.01.009_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00262-012-1347-9","article-title":"Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non\u2013small-cell lung cancer patients treated with first-line platinum-based chemotherapy","volume":"62","author":"Yao","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.cllc.2017.01.009_bib41","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/JTO.0b013e318260e106","article-title":"Prognostic models to predict survival in non\u2013small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab","volume":"7","author":"Hoang","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib42","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1471-2407-13-158","article-title":"Advanced lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non\u2013small-cell lung cancer (NSCLC): a retrospective review","volume":"13","author":"Jafri","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2017.01.009_bib43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/1066896913486694","article-title":"Toward personalized medicine of lung cancer: response to nontargeted therapy in invasive pulmonary adenocarcinoma as a function of tumor cell differentiation","volume":"21","author":"Hartel","year":"2013","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.cllc.2017.01.009_bib44","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1002\/cncr.26584","article-title":"Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome","volume":"118","author":"Solis","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2017.01.009_bib45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2008.07.017","article-title":"Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma","volume":"64","author":"Martins","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.009_bib46","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1183\/09031936.00018013","article-title":"EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype","volume":"43","author":"Warth","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cllc.2017.01.009_bib47","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3892\/or.2012.2009","article-title":"Thyroid transcription factor 1 represses the expression of Ki-67 and induces apoptosis in non\u2013small-cell lung cancer","volume":"28","author":"Zu","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.cllc.2017.01.009_bib48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3747\/co.21.2148","article-title":"Relationship of thyroid transcription factor 1 to EGFR status in non\u2013small-cell lung cancer","volume":"21","author":"Sheffield","year":"2014","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cllc.2017.01.009_bib49","series-title":"AJCC Cancer Staging Manual","author":"Edge","year":"2010"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730417300384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730417300384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:06:21Z","timestamp":1761505581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730417300384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1525730417300384"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2017.01.009","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non\u2013Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non\u2013Small-cell Lung Cancer Favor Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2017.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}